Table 2.

Clinical data of 21 primary non‐tonsillar oral diffuse large B‐cell lymphomas

Patient no.	Age (years)	Sex	Primary site	IPI	LDH >  normal values	Tumor size (maximum diameter; cm)	Ulcer	CS	Treatment	Relapse	Follow‐up period (months)	Follow‐up status
1	69	M	Hard palate	L	No	2.5	–	IE	CHOP + RT	+	59	Alive, FOD
2	57	F	Gingiva	L	No	2.5	+	IE	RT	–	79	Alive, FOD
3	65	F	Gingiva	LI	Yes	3.5	+	IE	R‐CHOP + RT	–	13	Alive, FOD
4	68	F	Gingiva	LI	No	3.5	+	IE	CHOP + RT	–	22	Alive, FOD
5	60	M	Gingiva	L	No	2	+	IE	R‐CHOP + RT	–	16	Alive, FOD
6	68	F	Gingiva	LI	Yes	5<	–	IE	NA	NA	NA	NA
7	62	M	Gingiva	LI	No	2, multiple	+	IE	R‐CHOP	–	19	Alive, FOD
8	74	F	Hard palate	L	No	3	–	IE	CHOP + RT	–	129	Alive, FOD
9	85	M	Soft palate	L	No	3.5	–	IE	NA	NA	NA	NA
10	76	M	Gingiva	L	No	4	+	IE	R‐THP‐COP + RT	–	33	Alive, FOD
11	53	M	Hard palate	L	No	2	–	IE	CHOP	NA	NA	NA
12	72	F	Gingiva	L	No	3	–	IE	NA	NA	NA	NA
13	85	M	Hard palate	L	No	3	–	IE	R‐CHOP	–	37	Alive, FOD
14	86	M	Soft palate	LI	Yes	2	+	IE	CHOP + RT	–	126	Alive, FOD
15	71	M	Buccal	L	No	4.5	+	IE	CHOP + RT	+	67	Alive, FOD
16	63	F	Hard palate	L	No	3	+	IE	CHOP + RT	NA	4	LTF
17	62	F	Gingiva	LI	Yes	1.5	+	IE	CHOP + RT	–	177	Alive, FOD
18	77	F	Gingiva	L	No	3.5	+	IIE	Partial resection + CHOP	–	31	Alive, FOD
19	57	M	Gingiva	L	No	3	–	IIE	R‐CHOP	–	52	Alive, FOD
20	71	F	Tongue	L	No	2.5	+	IIE	THP‐COP	–	34	Alive, FOD
21	67	M	Hard palate	LI	Yes	5<	+	IIE	CHOP + RT	–	29	Alive, FOD

CHOP, cyclophosphamide, adriamycin, vincristine, prednisolone; CS, clinical stage; F, female; FOD, free of disease; IPI, International Prognostic Index; L, low; LDH, lactate dehydrogenase; LI, low–intermediate; LTF, lost to follow up; M, male; NA, not available; R‐, with rituximab; RT, radiation; THP‐COP, cyclophosphamide, THP‐doxorubicin (pirarubicin), vincristine, prednisolone.